Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

Blood - 1 May 2014

Treon Steven P, Cao Yang, Xu Lian, Yang Guang, Liu Xia, Hunter Zachary R

Abstract excerpt

Whole genome sequencing has revealed activating somatic mutations in MYD88 (L265P) and CXCR4 in Waldenström macroglobulinemia (WM). CXCR4 somatic mutations in WM are the first ever reported in human cancer and are similar to nonsense (NS) and frameshift (FS) germline mutations found in warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome. We genotyped lymphoplasmacytic cells from 175 WM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bone Marrow

Share to Myeloid Differentiation Factor 88

Share to Receptors, CXCR4

Share to Treatment Outcome

Share to Waldenstrom Macroglobulinemia

Source

Identifiers

PMID: 24553177
DOI: 10.1182/blood-2014-01-550905

Genes

CXCR4
MYD88

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.PMID 24553177Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.Semantic proximity Read ↗

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Significances of MYD88L265P and CXCR4WHIM Mutations in Waldenstrom Macroglobulinemia.Semantic proximity Read ↗

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.Semantic proximity Read ↗

New treatment strategies for Waldenström macroglobulinemia.Semantic proximity Read ↗

Genomic Landscape of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.Semantic proximity Read ↗

MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Semantic proximity Read ↗

Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia.Semantic proximity Read ↗

Waldenstrom macroglobulinemia: genetics dictates clinical course.Semantic proximity Read ↗

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.